StockNews.AI
LLY
StockNews.AI
147 days

Lilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting

1. Eli Lilly presents preclinical data at AACR Annual Meeting, April 25-30. 2. Data includes LY4050784, a SMARCA2 inhibitor, showing synergistic effects. 3. LY4066434, a pan-KRAS inhibitor, demonstrates anti-tumor activity in models. 4. Both drug programs are enrolling Phase 1 studies for further evaluation. 5. The data may enhance LLY’s oncology portfolio and market position.

7m saved
Insight
Article

FAQ

Why Bullish?

The presentation of promising preclinical data can boost investor confidence in LLY's oncology pipeline, similar to effects seen with other companies like AstraZeneca after successful trial results.

How important is it?

The article discusses new agents that may significantly advance LLY’s oncology offerings, thus impacting future performance and growth potential.

Why Long Term?

The successful transition of these candidates to later trial phases can significantly improve LLY’s revenue potential long-term, akin to prior drug developments that led to substantial stock price increases.

Related Companies

FHTXAZN
, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple KRAS mutations will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25 - 30 in Chicago. In an oral presentation, Lilly, in collaboration with Foghorn Therapeutics, will present new preclinical data for LY4050784, a selective inhibitor of SMARCA2, in combination with chemotherapy, pembrolizumab, and KRAS inhibitors in preclinical models of SMARCA4 mutant cancers. Preclinical data for LY4066434, a pan-KRAS inhibitor that is highly selective over HRAS and NRAS, will also be presented. Both programs are currently enrolling Phase 1 studies.  Details on presentations are below: Presentation Title: LY4050784, a selective inhibitor of SMARCA2, demonstrates synergistic activity in combinations with pembrolizumab or KRAS inhibitorsAbstract Number: 3779Session Date & Time: Monday, April 28, 2:30-4:30 p.m. CSTSession Title: Continuum of Innovation: Biological Therapeutic AgentsPresenter: Nathan Brooks Presentation Title: LY4066434, an oral small molecule pan-KRAS inhibitor, demonstrates robust anti-tumor activity in KRAS-mutant models, including in the CNS Abstract Number: 4375Session Date & Time: Tuesday, April 29, 9 a.m.-12 p.m. CSTSession Title: RAS InhibitorsPresenter: Hong Gao For more information on Lilly's Oncology pipeline click here. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY Trademarks and Trade NamesAll trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Lilly's oncology pipeline, including therapies under development, and the timeline for future readouts, presentations, and other milestones relating to therapies under development and their clinical trials, and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, or that any of these therapies will receive initial regulatory approval or approvals for additional indications, as applicable, or be commercially successful. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release. SOURCE Eli Lilly and Company WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News